PDSB News and Press, PDS Biotechnology Corporation From 03/22/22

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...

PDS Biotechnology (NASDAQ:PDSB) is scheduled to announce FY earnings results on Wednesday, March 23rd, before market open. The consensus EPS Estimate is -$0.25 (+71.9% Y/Y) For further details see: PDS Biotechnology FY 2021 Earnings Preview

Phase 2 Enrollment Is On Schedule. PDS Biotechnology has announced that the National Cancer Institute (NCI) Phase 2 trial testing PDS0101 in a triple-therapy regimen has reached the target patient enrollment in one of its two treatment arms. This trial is testing PDS0101 in combination with tw...

Clinical-stage immunotherapy company, PDS Biotechnology (NASDAQ:PDSB), announced on Tuesday the achievement of a key enrollment target in Phase 2 clinical trial for a combination therapy involving its lead candidate PDS0101 in advanced HPV-associated cancers. The 56-patient trial led by Natio...

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Inf...

FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...

FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...

After four straight sessions of declines, the shares of PDS Biotechnology (PDSB +3.0%) are trading higher on Thursday after the clinical-stage biotech company reported initial safety data for an experimental drug combination from a mid-stage study in head and neck cancer. The Phase 2 VERSATIL...

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or signi...

PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level. For fur...